Cargando…

CD133 expression and MYCN amplification induce chemoresistance and reduce average survival time in pediatric neuroblastoma

OBJECTIVES: Neuroblastoma (NB) is the most common pediatric solid tumor derived from the sympathetic nervous system. MYCN is amplified in nearly half of patients with NB, and its association with rapid disease progression and poor outcome is controversial. Characterization of cancer stem cells (CSCs...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhong, Zhi-Yong, Shi, Bao-Jun, Zhou, Hui, Wang, Wen-Bo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2018
Materias:	Clinical Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5972240/ https://www.ncbi.nlm.nih.gov/pubmed/29322842 http://dx.doi.org/10.1177/0300060517732256

Ejemplares similares

MYCN Amplifications and Metabolic Rewiring in Neuroblastoma
por: Pouliou, Marialena, et al.
Publicado: (2023)

Implementation of the plasma MYCN/NAGK ratio to detect MYCN amplification in patients with neuroblastoma
por: Su, Yan, et al.
Publicado: (2020)

MYCN amplification and ATRX mutations are incompatible in neuroblastoma
por: Zeineldin, Maged, et al.
Publicado: (2020)

Extracellular Vesicle-Based Method for Detecting MYCN Amplification Status of Pediatric Neuroblastoma
por: Panachan, Jirawan, et al.
Publicado: (2022)

Heterogeneous MYCN amplification in neuroblastoma: a SIOP Europe Neuroblastoma Study
por: Berbegall, Ana P., et al.
Publicado: (2018)

Therapeutic potential of targeting MYCN: A case series report of neuroblastoma with MYCN amplification
por: Huang, Can, et al.
Publicado: (2020)

CCNB1IP1 prevents ubiquitination‐mediated destabilization of MYCN and potentiates tumourigenesis of MYCN‐amplificated neuroblastoma
por: Zhou, Yang, et al.
Publicado: (2023)

MYCN is amplified during S phase, and c-myb is involved in controlling MYCN expression and amplification in MYCN-amplified neuroblastoma cell lines
por: Aygun, Nevim, et al.
Publicado: (2019)

CT-Based Radiomics Signature With Machine Learning Predicts MYCN Amplification in Pediatric Abdominal Neuroblastoma
por: Chen, Xin, et al.
Publicado: (2021)

MYCN amplification confers enhanced folate dependence and methotrexate sensitivity in neuroblastoma
por: Lau, Diana T., et al.
Publicado: (2015)

Effects of preoperative chemotherapy on neuroblastoma with MYCN amplification: a surgeon’s perspective
por: Chui, Chanhon
Publicado: (2020)

MYCN amplification plus 1p36 loss of heterozygosity predicts ultra high risk in bone marrow metastatic neuroblastoma
por: Yue, Zhi‐Xia, et al.
Publicado: (2022)

Adverse outcome of infants with metastatic neuroblastoma, MYCN amplification and/or bone lesions: results of the French Society of Pediatric Oncology
por: Minard, V, et al.
Publicado: (2000)

Widespread Dysregulation of MiRNAs by MYCN Amplification and Chromosomal Imbalances in Neuroblastoma: Association of miRNA Expression with Survival
por: Bray, Isabella, et al.
Publicado: (2009)

MYCN Amplification Is Associated with Reduced Expression of Genes Encoding γ-Secretase Complex and NOTCH Signaling Components in Neuroblastoma
por: Agarwal, Prasoon, et al.
Publicado: (2023)

MYCN Function in Neuroblastoma Development
por: Otte, Jörg, et al.
Publicado: (2021)

MYCN and Metabolic Reprogramming in Neuroblastoma
por: Bansal, Mohit, et al.
Publicado: (2022)

Metastasis in neuroblastoma: the MYCN question
por: Bhavsar, Swapnil Parashram
Publicado: (2023)

Genetic Instability and Intratumoral Heterogeneity in Neuroblastoma with MYCN Amplification Plus 11q Deletion
por: Villamón, Eva, et al.
Publicado: (2013)

Druggable epigenetic suppression of interferon-induced chemokine expression linked to MYCN amplification in neuroblastoma
por: Seier, Johanna A, et al.
Publicado: (2021)

Serum-Based Quantification of MYCN Gene Amplification in Young Patients with Neuroblastoma: Potential Utility as a Surrogate Biomarker for Neuroblastoma
por: Yagyu, Shigeki, et al.
Publicado: (2016)

Effects of novel pyrrolomycin MP1 in MYCN amplified chemoresistant neuroblastoma cell lines alone and combined with temsirolimus
por: McGuire, Timothy R., et al.
Publicado: (2019)

Chromosomal CGH identifies patients with a higher risk of relapse in neuroblastoma without MYCN amplification
por: Schleiermacher, G, et al.
Publicado: (2007)

Clinical Characteristics and Outcome of Patients with Neuroblastoma Presenting Genomic Amplification of Loci Other than MYCN
por: Guimier, Anne, et al.
Publicado: (2014)

MYCN Amplification Is Associated with Repressed Cellular Immunity in Neuroblastoma: An In Silico Immunological Analysis of TARGET Database
por: Zhang, Peng, et al.
Publicado: (2017)

Droplet digital PCR as an alternative to FISH for MYCN amplification detection in human neuroblastoma FFPE samples
por: Somasundaram, Dinesh Babu, et al.
Publicado: (2019)

Ferroptosis vulnerability in MYCN‐driven neuroblastomas
por: Dasgupta, Shayani, et al.
Publicado: (2022)

Diagnostic value of CT and MRI combined with serum LDH, NSE, CEA, and MYCN in pediatric neuroblastoma
por: Hao, Jumei, et al.
Publicado: (2023)

An integrative radiological, histopathological and molecular analysis of pediatric pontine histone-wildtype glioma with MYCN amplification (HGG-MYCN)
por: Tauziède-Espariat, A., et al.
Publicado: (2019)

MYCN upregulates the transsulfuration pathway to suppress the ferroptotic vulnerability in MYCN-amplified neuroblastoma
por: Floros, Konstantinos V., et al.
Publicado: (2022)

Impact of 11q Loss of Heterozygosity Status on the Response of High-Risk Neuroblastoma With MYCN Amplification to Neoadjuvant Chemotherapy
por: Lu, Xian-Ying, et al.
Publicado: (2022)

MYCN transcriptionally represses CD9 to trigger an invasion-metastasis cascade in neuroblastoma
por: Fabian, Johannes, et al.
Publicado: (2015)

MYCN gene amplification is a powerful prognostic factor even in infantile neuroblastoma detected by mass screening
por: Iehara, T, et al.
Publicado: (2006)

Binomial Mitotic Segregation of MYCN-Carrying Double Minutes in Neuroblastoma Illustrates the Role of Randomness in Oncogene Amplification
por: Lundberg, Gisela, et al.
Publicado: (2008)

cDNA array-CGH profiling identifies genomic alterations specific to stage and MYCN-amplification in neuroblastoma
por: Chen, Qing-Rong, et al.
Publicado: (2004)

Differential Clinical Significance of Neurotrophin-3 Expression according to MYCN Amplification and TrkC Expression in Neuroblastoma
por: Seo, Eunseop, et al.
Publicado: (2019)

Hypoxia-Dependent Expression of TG2 Isoforms in Neuroblastoma Cells as Consequence of Different MYCN Amplification Status
por: Currò, Monica, et al.
Publicado: (2020)

Genetic Alterations and Resectability Predict Outcome in Patients with Neuroblastoma Assigned to High-Risk Solely by MYCN Amplification
por: Berthold, Frank, et al.
Publicado: (2021)

MYCN acts as a direct co-regulator of p53 in MYCN amplified neuroblastoma
por: Agarwal, Saurabh, et al.
Publicado: (2018)

A MYCN-independent mechanism mediating secretome reprogramming and metastasis in MYCN-amplified neuroblastoma
por: Zhang, Hai-Feng, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_qld94dac823vshcpegj2ooseab